ChristopherJohnCutieMDMBA

Urology • Boston, MA

Surgical Oncology

Chief Medical Officer at TARIS

Join to view full profile

Dr. Cutie is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Cutie's full profile

Already have an account?

Office
101 Nicolls Rd
Boston, MA 11794
Phone+1 617-726-2797

Fax+1 617-726-6131

Education & Training

Massachusetts General Hospital/Harvard Medical SchoolResidency, Urology, 2005 - 2008
Massachusetts General HospitalResidency, Surgery, 2003 - 2005
Yale School of MedicineClass of 2003

Certifications & Licensure

MA State Medical License 2008 - 2023
American Board of Urology Urology

Clinical Trials

Safety and Tolerability of TAR-302-5018 in Subjects With Idiopathic Overactive Bladder Start of enrollment: 2017 Apr 04
Completed
Phase 1
Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer Start of enrollment: 2019 Jan 02
Terminated
Phase 1

Publications & Presentations

PubMed

4 citations
The Safety, Tolerability, and Preliminary Efficacy of a Gemcitabine-releasing Intravesical System (TAR-200) in American Urological Association-defined Intermediate-ris...
F Johannes P van Valenberg, Antoine G van der Heijden, Christopher J Cutie, Sumeet Bhanvadia, Kirk A Keegan
European Urology Open Science. 2024-04-01
Reply by Authors.
Mark D Tyson, David Morris, Juan Palou, Oscar Rodriguez, Maria Carmen Mir
The Journal of Urology. 2023-05-01
6 citations
Safety, Tolerability, and Preliminary Efficacy of TAR-200 in Patients With Muscle-invasive Bladder Cancer Who Refused or Were Unfit for Curative-intent Therapy: A Phas...
Mark D Tyson, David Morris, Juan Palou, Oscar Rodriguez, Maria Carmen Mir
The Journal of Urology. 2023-05-01

Other

Overview of vasectomy
Cutie CJ, Ongaro TJ
http://www.uptodate.com/contents/overview-of-vasectomy
UpToDate, Wolters Kluwer Health - 2009-09-23

Press Mentions

New Data from TAR-200 Phase 2b SunRISe-1 Study Show 84 Percent Complete Response Rate in Patients with High-Risk Non-Muscle-Invasive Bladder CancerSeptember 16th, 2024
New Data from TAR-200 Phase 2b SunRISe-1 Study Show 84 Percent Complete Response Rate in Patients with High-Risk Non-Muscle-Invasive Bladder CancerSeptember 15th, 2024
Janssen Reports First Results from Phase 2 SunRISe-1 Study of TAR-200 and Anti- PD-1 Antibody Cetrelimab in Patients with Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder CancerApril 30th, 2023
Join now to see all

Other Languages

German